Active, not recruitingPhase 3NCT05739383
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Studying Disorder of lipid metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL(drug)
- Enrollment
- 14012 target
- Eligibility
- 40-79 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- Central Alabama Research, Birmingham, Alabama, United States
- UAB St Vincents, Birmingham, Alabama, United States
- Eastern Shore Research Institute, Fairhope, Alabama, United States
- G and L Research LLC, Foley, Alabama, United States
- Longwood Research, Huntsville, Alabama, United States
- CB Flock Corporation, Mobile, Alabama, United States
- Mobile Heart Specialists, Mobile, Alabama, United States
- The Center for Clinical Trials, Saraland, Alabama, United States
- Synexus, Glendale, Arizona, United States
- Lenzmeier Family Practice, Glendale, Arizona, United States
- Clinical Research Inst of Arizona, Sun City West, Arizona, United States
- Clinical Research Advantage Fiel Family and Sports Med, PC, Tempe, Arizona, United States
- Synexus Clinical Research US Inc, Tucson, Arizona, United States
- Cardiovascular Res Found, Beverly Hills, California, United States
- National Heart Institute, Beverly Hills, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05739383 on ClinicalTrials.govOther trials for Disorder of lipid metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06695325Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)Tameside General Hospital
- RECRUITINGPHASE1NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLDCorcept Therapeutics
- ACTIVE NOT RECRUITINGPHASE2NCT07028749Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolMarea Therapeutics
- ENROLLING BY INVITATIONPHASE4NCT06845345Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)Carmen Dietvorst
- RECRUITINGPHASE3NCT06643130Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and DyslipidemiaJW Pharmaceutical
- ENROLLING BY INVITATIONNANCT06822621Functional Cereal Products and Contribution to the Regulation of Metabolism and Obesity-induced Chronic Low-grade Inflammation.Harokopio University
- ACTIVE NOT RECRUITINGPHASE3NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionMerck Sharp & Dohme LLC
- RECRUITINGNCT06206759Vitamin C Administration and Triglycerides Level in Critical Care PatientsMeir Medical Center